December 28, 2011
With sales of ¥57.6 billion, the Alzheimer’s disease treatment Aricept (donepezil) displaced the angiotensin II receptor blocker (ARB) Blopress (candesartan) as Japan’s top-selling ethical drug in the first half of FY2011. Blopress, which maintained the leading position for seven periods...read more